West Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow WST
West Pharmaceutical Services, Inc. (WST) Operating cash flow
West Pharmaceutical Services, Inc.'s operating cash flow for fiscal 2025 was $754.8M, up 15.5% from $653.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was $662.2M. Over the past ten years it has ranged from $212.4M (fiscal 2015) to $776.5M (fiscal 2023); the current reading is higher than 91% of that period. West Pharmaceutical Services, Inc. ranks 9th of 54 Medical Instruments & Supplies companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $754.8M | 15.52% |
| FY2024 | $653.4M | (15.85%) |
| FY2023 | $776.5M | 7.25% |
| FY2022 | $724.0M | 23.97% |
| FY2021 | $584.0M | 23.60% |
| FY2020 | $472.5M | 28.68% |
| FY2019 | $367.2M | 27.23% |
| FY2018 | $288.6M | 9.61% |
| FY2017 | $263.3M | 20.01% |
| FY2016 | $219.4M | 3.30% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $124.0M | 37.93% |
| Mar 2026 | $89.9M | (64.20%) |
| Dec 2025 | $251.1M | 27.33% |
| Sep 2025 | $197.2M | 11.35% |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| BDX Becton, Dickinson and Company compare | $4.0B |
| MDLN Medline Inc. compare | $3.1B |
| ALC Alcon compare | $2.3B |
| RMD ResMed Inc. compare | $1.8B |
| BAX Baxter International Inc. compare | $1.3B |
| COO The Cooper Companies, Inc. compare | $1.0B |
| WST West Pharmaceutical Services, Inc. | $662.2M |
| SOLV Solventum Corporation compare | $209.0M |
| RGEN Repligen Corporation compare | $134.9M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on WST
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement